Genelux Corporation/$GNLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Ticker
$GNLX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
24
ISIN
US36870H1032
Website
GNLX Metrics
BasicAdvanced
$130M
-
-$0.88
-0.52
-
Price and volume
Market cap
$130M
Beta
-0.52
52-week high
$4.74
52-week low
$1.99
Average daily volume
139K
Financial strength
Current ratio
4.675
Quick ratio
4.565
Long term debt to equity
4.858
Total debt to equity
5.987
Profitability
EBITDA (TTM)
-31.187
Management effectiveness
Return on assets (TTM)
-61.65%
Return on equity (TTM)
-131.36%
Valuation
Price to book
4.35
Price to tangible book (TTM)
4.35
Price to free cash flow (TTM)
-5.133
Free cash flow yield (TTM)
-19.48%
Free cash flow per share (TTM)
-67.79%
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-10.24%
3-year earnings per share growth (CAGR)
-22.46%
GNLX News
AllArticlesVideos
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
GlobeNewsWire·3 days ago
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genelux Corporation stock?
Genelux Corporation (GNLX) has a market cap of $130M as of July 10, 2025.
What is the P/E ratio for Genelux Corporation stock?
The price to earnings (P/E) ratio for Genelux Corporation (GNLX) stock is 0 as of July 10, 2025.
Does Genelux Corporation stock pay dividends?
No, Genelux Corporation (GNLX) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Genelux Corporation dividend payment date?
Genelux Corporation (GNLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Genelux Corporation?
Genelux Corporation (GNLX) has a beta rating of -0.52. This means that it has an inverse relation to market volatility.